Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS Regarding CY 2020 CLFS Preliminary Payment Determinations
-
ACMG Comments to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act Discussion Draft
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs
-
Group Sign-on Letter to Congress Urging Modernization of the Clinical Laboratory Improvement Amendments (CLIA)